119 related articles for article (PubMed ID: 7697692)
1. Effect of insulin-glipizide combination on skeletal muscle capillary basement membrane width in diabetic patients.
Camerini-Davalos RA; Bloodworth JM; Velasco CA; Reddi AS
Clin Ther; 1994; 16(6):952-61. PubMed ID: 7697692
[TBL] [Abstract][Full Text] [Related]
2. Sulfonylurea-induced decrease of muscle capillary basement membrane thickness in diabetes.
Camerini-Davalos RA; Velasco CA; Glasser M; Bloodworth JM
Diabetes Res Clin Pract; 1988 Jul; 5(2):113-23. PubMed ID: 3046878
[TBL] [Abstract][Full Text] [Related]
3. Delay of progression of diabetic microangiopathy.
Camerini-Davalos RA; Velasco CA; Reddi AS; Glasser M; Bloodworth JM
Metabolism; 1988 Feb; 37(2 Suppl 1):10-8. PubMed ID: 2963192
[TBL] [Abstract][Full Text] [Related]
4. Drug-induced reversal of early diabetic microangiopathy.
Camerini-Davalos RA; Velasco C; Glasser M; Bloodworth JM
N Engl J Med; 1983 Dec; 309(25):1551-6. PubMed ID: 6656850
[TBL] [Abstract][Full Text] [Related]
5. Effect of glycemic control on microvascular complications in patients with type I diabetes mellitus.
Rosenstock J; Friberg T; Raskin P
Am J Med; 1986 Dec; 81(6):1012-8. PubMed ID: 3541587
[TBL] [Abstract][Full Text] [Related]
6. The effect of diabetic control on the width of skeletal-muscle capillary basement membrane in patients with Type I diabetes mellitus.
Raskin P; Pietri AO; Unger R; Shannon WA
N Engl J Med; 1983 Dec; 309(25):1546-50. PubMed ID: 6361554
[TBL] [Abstract][Full Text] [Related]
7. Improved diabetes control reduces skeletal muscle capillary basement membrane width in insulin-dependent diabetes mellitus.
Rosenstock J; Challis P; Strowig S; Raskin P
Diabetes Res Clin Pract; 1988 Feb; 4(3):167-75. PubMed ID: 3359916
[TBL] [Abstract][Full Text] [Related]
8. The effect of aldose reductase inhibition with ponalrestat on the width of the capillary basement membrane in diabetes mellitus.
Ramirez LC; Arauz C; Pruneda L; Hammon K; Rosenstock J; Raskin P
Diabetes Res Clin Pract; 1991 Feb; 11(2):73-80. PubMed ID: 1902410
[TBL] [Abstract][Full Text] [Related]
9. Muscle capillary basement membrane width in patients with vacor-induced diabetes mellitus.
Feingold KR; Lee TH; Chung MY; Siperstein MD
J Clin Invest; 1986 Jul; 78(1):102-7. PubMed ID: 3722372
[TBL] [Abstract][Full Text] [Related]
10. Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes. VA feasibility study on glycemic control and complications (VA CSDM).
Abraira C; Henderson WG; Colwell JA; Nuttall FQ; Comstock JP; Emanuele NV; Levin SR; Sawin CT; Silbert CK
Diabetes Care; 1998 Apr; 21(4):574-9. PubMed ID: 9571345
[TBL] [Abstract][Full Text] [Related]
11. [Effect of glipizide on glycemic control and peripheral insulin sensitivity in type 1 diabetics].
Leblanc H; Thote A; Chatellier G; Passa P
Diabete Metab; 1990; 16(2):93-7. PubMed ID: 2196193
[TBL] [Abstract][Full Text] [Related]
12. Combination of insulin with glipizide increases peripheral glucose disposal in secondary failure type 2 diabetic patients.
Simpson HC; Sturley R; Stirling CA; Reckless JP
Diabet Med; 1990 Feb; 7(2):143-7. PubMed ID: 2137755
[TBL] [Abstract][Full Text] [Related]
13. Relationship of muscle capillary basement membrane to renal structure and function in diabetes mellitus.
Ellis EN; Mauer SM; Goetz FC; Sutherland DE; Steffes MW
Diabetes; 1986 Apr; 35(4):421-5. PubMed ID: 3956879
[TBL] [Abstract][Full Text] [Related]
14. Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. The Glipizide Gastrointestinal Therapeutic System Study Group.
Simonson DC; Kourides IA; Feinglos M; Shamoon H; Fischette CT
Diabetes Care; 1997 Apr; 20(4):597-606. PubMed ID: 9096986
[TBL] [Abstract][Full Text] [Related]
15. Enzyme activities as a predictor of diabetic vasculopathy.
Camerini-Davalos RA; Velasco CA; Glasser M; Bloodworth JM
Am J Med; 1986 Apr; 80(4):574-82. PubMed ID: 2938472
[TBL] [Abstract][Full Text] [Related]
16. Effects of short-term insulin therapy upon therapeutic response to glipizide.
Schwartz SL; Fischer JS; Kipnes MS; Boyle M
Am J Med; 1987 Sep; 83(3A):22-30. PubMed ID: 3307403
[TBL] [Abstract][Full Text] [Related]
17. Conversion from low-dose insulin therapy to glipizide in patients with non-insulin-dependent diabetes mellitus.
Rosenstock J; Meisel A; Raskin P
Am J Med; 1987 Sep; 83(3A):10-5. PubMed ID: 3307402
[TBL] [Abstract][Full Text] [Related]
18. Studies of muscle capillary basement membranes in normal subjects, diabetic, and prediabetic patients.
Siperstein MD; Unger RH; Madison LL
J Clin Invest; 1968 Sep; 47(9):1973-99. PubMed ID: 5675423
[TBL] [Abstract][Full Text] [Related]
19. The use of glipizide combined with intensive insulin treatment for the induction of remissions in new onset adult type I diabetes.
Selam JL; Woertz L; Lozano J; Robinson M; Chan E; Charles MA
Autoimmunity; 1993; 16(4):281-8. PubMed ID: 8025207
[TBL] [Abstract][Full Text] [Related]
20. Correlation between erythrocyte aldose reductase activity and the width of skeletal-muscle capillary basement membrane in insulin-dependent diabetes mellitus.
Hamada Y; Hammon K; Raskin P
J Diabetes Complications; 1992; 6(4):242-6. PubMed ID: 1482782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
